Evaluation of hepatocyteprotective and anti-hepatitis B virus properties of Cichoric acid from Cichorium intybus leaves in cell culture.
Hepatitis B is the most common serious liver infection in the world. To date, there is still no complete cure for chronic hepatitis B. Natural caffeic acid analogues possess prominent antiviral activity, especially anti-hepatitis B virus (HBV) and anti-human immunodeficiency virus effects. Cichoric acid is a caffeic acid derivative from Cichorium intybus. In the study, the anti-hepatitis B property of cichoric acid was evaluated by the D-galactosamine (D-GalN)-induced normal human HL-7702 hepatocyte injury model, the duck hepatitis B virus (DHBV)-infected duck fetal hepatocytes and the HBV-transfected cell line HepG2.2.15 cells, respectively. The results showed that cichoric acid attenuated significantly D-GalN-induced HL-7702 hepatocyte injury at 10-100 µg/mL and produced a maximum protection rate of 56.26%. Moreover, cichoric acid at 1-100 µg/mL inhibited markedly DHBV DNA replication in infected duck fetal hepatocytes. Also, cichoric acid at 10-100 µg/mL reduced significantly the hepatitis B surface and envelope antigen levels in HepG2.2.15 cells and produced the maximum inhibition rates of 79.94% and 76.41%, respectively. Meanwhile, test compound at 50-100 µg/mL inhibited markedly HBV DNA replication. In conclusion, this study verifies the anti-hepatitis B effect of cichoric acid from Cichorium intybus leaves. In addition, cichoric acid could be used to design the antiviral agents.
Zhejiang Provincial Key Laboratory of Biometrology and Inspection & Quarantine, Department of Pharmacy, College of Life Sciences, China Jiliang University.
Hong-Li
HL
Zhang
Ling-Hao
LH
Dai
Yi-Hang
YH
Wu
Xiao-Ping
XP
Yu
Yong-Yong
YY
Zhang
Rong-Fa
RF
Guan
Tao
T
Liu
Jun
J
Zhao
D000818:Animals; D002109:Caffeic Acids / Q000302:isolation & purification / Q000493:pharmacokinetics*; D002470:Cell Survival / Q000187:drug effects; D018651:Cichorium intybus / Q000737:chemistry*; D019610:Cytoprotection / Q000187:drug effects; D004279:DNA, Viral / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D004372:Ducks; D005688:Galactosamine / Q000494:pharmacology; D056945:Hep G2 Cells; D006514:Hepatitis B Surface Antigens / Q000378:metabolism; D015611:Hepatitis B Virus, Duck / Q000187:drug effects* / Q000235:genetics / Q000254:growth & development; D022781:Hepatocytes / Q000187:drug effects* / Q000821:virology; D006801:Humans; D015394:Molecular Structure; D018515:Plant Leaves / Q000737:chemistry; D020011:Protective Agents / Q000302:isolation & purification / Q000494:pharmacology*; D013386:Succinates / Q000302:isolation & purification / Q000493:pharmacokinetics*; D014779:Virus Replication / Q000187:drug effects
D002109:Caffeic Acids; D004279:DNA, Viral; D006514:Hepatitis B Surface Antigens; D020011:Protective Agents; D013386:Succinates; D005688:Galactosamine; C100435:chicoric acid